Glycosylation products as toxic mediators of diabetic complications

Michael Brownlee

Research output: Contribution to journalReview articlepeer-review

90 Scopus citations


Hyperglycemia causes excessive amounts of irreversible advanced glycosylation end products (AGEPs) to accumulate on long-lived extracellular matrix proteins and probably also on DNA in tissues that develop diabetic complications. AGEPs induce permanent abnormalities in extracellular protein cross-linking, cell-matrix interactions, and DNA structure in vitro. Pharmacologically inhibiting AGEP formation in long-term diabetic animals prevents both retinal capillary pathology and thickening of the glomerular basement membrane.

Original languageEnglish (US)
Pages (from-to)159-166
Number of pages8
JournalAnnual Review of Medicine
StatePublished - 1991
Externally publishedYes


  • Aminoguanidine
  • Coagulation
  • DNA
  • Diabetes
  • Extracellular matrix
  • Growth factors
  • Macrophages
  • Pharmacology
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Glycosylation products as toxic mediators of diabetic complications'. Together they form a unique fingerprint.

Cite this